Ardelyx (ARDX) reported $97.66 million in revenue for the quarter ended June 2025, representing a year-over-year increase of 33.4%. EPS of -$0.08 for the same period compares to -$0.07 a year ago.
The reported revenue represents a surprise of +15.39% over the Zacks Consensus Estimate of $84.64 million. With the consensus EPS estimate being -$0.13, the EPS surprise was +38.46%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Ardelyx performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Product sales, net: $90.08 million versus $81.64 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +24.1% change.
- Product sales- IBSRELA: $65.05 million compared to the $57.93 million average estimate based on six analysts.
- Product sales- XPHOZAH: $25.03 million compared to the $23.7 million average estimate based on six analysts.
- Revenues- Licensing: $0.02 million versus $0.15 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +5.3% change.
- Revenues- Product supply: $6.19 million versus the three-analyst average estimate of $2.08 million. The reported number represents a year-over-year change of +47476.9%.
- Non-cash royalty revenue related to the sale of future royalties: $1.38 million compared to the $1.07 million average estimate based on two analysts.
View all Key Company Metrics for Ardelyx here>>>
Shares of Ardelyx have returned +1.4% over the past month versus the Zacks S&P 500 composite's +0.6% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ardelyx, Inc. (ARDX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
